CompletedNot Applicable

Anti-Müllerian Hormone and Embryo Aneuploidy

Chile300 participantsStarted 2018-01-01

Plain-language summary

The goal of this observational study is to determine is there an association between the rates of aneuploidy and the different ranges of serum Antimullerian hormone (AMH) levels. Retrospective, single-centre study of patients undergoing IVF and preimplantation genetic testing with aneuploidy at the blastocyst stage between January 2018 and December 2022.

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All started cycles planned to be followed by preimplantation genetic testing for aneuploidies (PGT-A). PGT-A is proposed to the couples for the following reasons: advanced maternal age, recurrent miscarriage, repeated implantation failure or severe male infertility factor; it is also offered to all patients with a good prognosis who desired information regarding the ploidy status of their embryos. Exclusion Criteria: * Data from oocyte donation cycles

What they're measuring

Aneuplody rate

Timeframe: 4 years

Trial details

NCT IDNCT05723016

SponsorClinica de la Mujer Medicina Reproductiva, Chile

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-12-31

View on ClinicalTrials.gov More Infertility trials